IMPORTANCE MicroRNAs (miRNAs) are promising multiple sclerosis (MS) biomarkers. Establishing the association between miRNAs and magnetic resonance imaging (MRI) measures of disease severity will help define their significance and potential impact.
Previous studies showed changes in miRNA expression in brain tissue, serum and plasma, and immune cells from patients with MS and in experimental autoimmune encephalomyelitis. [30] [31] [32] [33] Previous studies have also shown associations between MS disability or disease progression and the expression of miRNAs. 34, 35 Magnetic resonance imaging measures of lesions and atrophy aid in defining the pathobiology reflected by a candidate biomarker. 36 Since miRNAs regulate several cellular pathways, we hypothesized that different miRNA expression patterns would show associations with specific MRI measures of cerebral and spinal cord involvement.
Methods

Participants
As part of the Comprehensive Longitudinal Investigation of Multiple Sclerosis cohort study of clinical, MRI, and blood phenotyping in more than 2000 patients at Brigham and Women's Hospital, 37 we retrospectively identified patients with
(1) age 18 to 55 years, (2) MS diagnosis, 38 (3) absence of other major medical disorders, and (4) no more than 30 days between serum and brain MRI acquisition (cohort 1) or both spine and brain MRI acquisition (cohort 2). Patients were evaluated by an MS specialist at the time of MRI for neurologic disability by the Expanded Disability Status Scale (EDSS) score, an ordinal scale ranging from low (0) to high (10) disability. 39 Two independent cohorts (eTable 1 in the Supplement) were tested and analyzed for miRNA-MRI associations. Cohort 1 had 41 participants (7 [17.1%] men), with a mean (SD) age of 47.7 (9.5) years; cohort 2 had 79 participants (26 [32.9%] men), with a mean (SD) age of 43.0 (7.5) years. The study was conducted from December 2013 to April 2016. The study was approved by the Partners Health Care Human Research Committee. The participants provided written informed consent; there was no financial compensation.
Samples
Serum samples were collected in red-top Vacutainer tubes without additives, centrifuged at 2000 rpm for 10 minutes to separate serum, and stored at −70°C until RNA extraction. Isolation of RNA was then performed (miRcury kit; Exiqon) and converted to complementary DNA using a synthesis kit (Exiqon). Prepared complementary DNA samples were stored at −20°C. Locked nucleic acid, green-based, real-time quantitative polymerase chain reaction Human Panel I and II (LNA-SYBR; Exiqon) containing 652 miRNAs and 752 miRNAs were used for profiling the first set and second sets, respectively. Normalization was performed using the mean miRNA expression of 10 miRNAS (hsa.let.7d.3p, hsa.miR.103a.3p, hsa.miR.106a.5p, hsa.miR.126.3p, hsa.miR.15b.5p, hsa.miR.19a.3, hsa.miR.20a.5p, hsa.miR.30b.5p, hsa.miR.425.5p, and hsa.miR.92a.3p), with the best stability index determined by NormFinder software. Normalized cycle quantification (Cq) was calculated as mean Cq -assay Cq.
MRI Acquisition
Patients were scanned on one of two 1.5T MRI units (Signa; GE Healthcare). For brain imaging, the sequences covered the whole head; were free of inter-section gaps; and included (1) axial, T2-weighted, conventional spin-echo dual-echo (repetition time (TR)/echo time 1 (TE1)/TE2, 3000/30/80 milliseconds; voxel size, 0.9375 × 0.9375 × 3 mm); (2) axial T1-weighted spin-echo (TR/TE, 467-733/20 milliseconds; voxel size, 0.9375 × 0.9375 × 3 mm); (3) (cohort 2 only) sagittal, 3-dimensional, magnetization-prepared rapid gradient-echo
MRI Analysis
Lesion Measures Whole-brain T1 hypointense (T1LV) and T2 hyperintense (T2LV) lesion volume (both cohorts) and whole cervical (C1 to C7) spinal cord T2LV (cohort 2) were expert traced using an edgefinding tool in Jim, version 7 software (Xinapse Systems Ltd, http://www.xinapse.com/). Brain T2 lesions required hyperintensity on both the early-and late-echo T2 images. Brain T1 hypointense lesions (black holes) were defined as containing some degree of visible hyperintensity on the T2 images but were free of gadolinium enhancement (to reduce the detection of benign and transient lesions). 40 As an index of the destructive potential of the lesions, we calculated the intrapatient ratio of T1LV to T2LV (T1:T2) based on its unique and valuable role in previous studies.
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Brain Atrophy For cohort 2, given the availability of a high-resolution image set, we used a fully automated algorithm to derive normalized wholebrain parenchymal (BPV) and GM (GMV) volumes (SIENAX, version 5.0; Analysis Group, http://fsl.fmrib.ox.ac.uk). 14, 43 Given the ineffective contouring of the deep central and posterior fossa GM from the SIENAX output, we performed manual masking of the GMV maps to remove those regions to calculate the cortical GMV (cGMV). For cohort 1 ( Figure 1 ), we relied on the dual-echo images to estimate brain atrophy using a fully automated pipeline (SPM, version 12; Wellcome Trust Centre for Neuroimaging, http: //www.fil.ion.ucl.ac.uk/spm/). This derived brain parenchymal fraction (BPF) (a validated estimation of whole-brain atrophy 6 ) normalized as the ratio of brain parenchymal tissue (GM plus white matter) volume divided by the intracranial volume. 44 We also calculated the global cerebral GM fraction (GMF) in an analogous manner.
Spinal Cord Atrophy
In cohort 2, axial T2-weighted images of the cervical cord (C1-C5) were applied to a validated active surface tool 45 using the Jim, version 7 software package. Manual adjustments were made as necessary to capture the spinal cord contour. Spinal cord volume from C1 to C5 was normalized by dividing by the number of axial sections 46 to generate the upper cervical spinal cord area (UCCA). Our group has previously shown that cord volumes derived from T2-weighted images are similar to those obtained from T1-weighted images.
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Reliability and Blinding Analysis of MR images was performed by operators (F.K., R.C., S. Tauhid, S. Tummala, S.L.D., and G.K.) blinded to clinical and biomarker information. Five metrics required operator input (brain T2LV, brain T1LV, cGMV, UCCA, and spinal cord T2LV). Regarding brain T2LV, brain T1LV, and UCCA, our procedures and their high reliability have been well established in previously published studies. 47, 48 In the present data set, intrarater reliability was high as assessed from 5 randomly chosen cases. For spinal cord T2LV, the mean coefficient of variation was 3.53%; for cGMV, the mean coefficient of variation was 0.44%.
Statistical Analysis
Spearman correlation coefficients (r s ) estimated the association between miRNA expression (normalized Cq) and MRI and disability (EDSS score). Spearman correlations were used so that participants with miRNA levels below detection limits (missing or undetected values) could contribute to the analysis. Undetected expression values were assigned a value lower than the smallest observed value from all participants. P Values were adjusted for multiple comparisons using the false discovery rate. The miRNA-MRI associations were observed as either pathogenic, shown by high miRNA expression associated with high MRI 
Correlation Between miRNAs and MRI
The 10 miRNAs showing the strongest MRI association in each cohort are provided in Tables 1 and 2 (eTable 3 and eTable 4 in the Supplement present all correlations). In cohort 1, the miRNAs that demonstrated strong correlations were similar for BPF and GMF. However, the miRNAs associated with lesions (T2LV and T1:T2 ratio) were mostly different from those associated with atrophy, suggesting different pathologic processes underlying focal lesions (inflammatory demyelination) vs neurodegeneration (axonal and neuronal loss). Similar to those in cohort 1, miRNAs in cohort 2 that showed a strong correlation with whole-brain atrophy also indicated a strong correlation with cerebral GM atrophy. However, a different set of miRNAs correlated with spinal cord vs brain atrophy. In addition, only a small overlap was found between miRNAs associated with brain vs spinal cord T2LV. Thus, there was a topographic specificity in brain-vs spinal cord-related miRNAs. Although we found several miRNAs associated with MRI outcomes, none of these remained significant after false discovery rate correction.
Correlations Common Between miRNAs and MRI in Both Cohorts
Four miRNAs showed similar significant protective correlations with T1:T2 in both cohorts, with the highest for hsa.miR.143.3p (cohort 1: Spearman correlation coefficient r s = −0.452, P = .003; cohort 2: r s = −0.225, P = .046); the others included hsa.miR.142.5p (cohort 1: r s = −0.424, P = .006; cohort 2: r s = −0.226, P = .045), hsa.miR.181c.3p (cohort 1:
r s = −0.383, P = .01; cohort 2: r s = −0.222, P = .049), and hsa.miR.181c.5p (cohort 1: r s = −0.433, P = .005; cohort 2:
r s = −0.231, P = .04). In the 2 cohorts, hsa.miR.486.5p (cohort 1: r s = 0.348, P = .03; cohort 2: r s =0 .254,P = .02) and hsa.miR.92a.3p (cohort 1: r s = 0.392, P = .01; cohort 2: r s = 0.222, P = .049) showed similar significant pathogenic correlations with T1:T2; hsa.miR.375 (cohort 1: r s = −0.345, P = .03; cohort 2: r s =−0.257 ,P = .022) and hsa.miR.629.5p (cohort 1: r s = −0.350, P = .03; cohort 2: r s = −0.269, P =. 02 ) showed significant pathogenic correlations with brain atrophy. Thus, a common set of miRNAs was associated with measures of destructive pathology/neurodegeneration in both cohorts. The miRNAs that were significantly correlated in the same direction with MRI are summarized in Table 3 and Figure 2 . Four miRNAs (hsa.miR.142.5p, hsa.miR.143.3p, hsa.miR.181c.3p, and hsa.miR.181c.5p) were significantly correlated (protective) with T1:T2 ratio in both cohorts, with hsa.miR.143.3p correlating the highest (cohort 1: r s = −0.452, P = .003; cohort 2: r s = −0.225, P = .046). Two miRNAs (hsa.miR.486.5p and hsa.miR.92a.3p) significantly correlated (pathogenic) with T1:T2 ratio in both cohorts. Two miRNAs (hsa.miR.375 and hsa.miR.629.5p) significantly correlated (pathogenic) with brain atrophy in both cohorts. Thus, a common set of miRNAs was associated with measures of destructive pathology/neurodegeneration in both cohorts.
Correlations Between miRNAs and Disability
Several miRNAs showed significant associations with EDSS score in both cohorts (Tables 1 and 2 ). Seven of these associations remained significant after false discovery rate correction (Table 1) .
Discussion
We evaluated the association between serum miRNA and MRI measures of disease severity in MS, including lesions and atrophy, in the brain and spinal cord. Several key findings emerged: both protective and pathogenic associations were found between miRNAs and MRI; a topographic specificity, different between the brain and spinal cord, was identified; a pathobiologic specificity was found with T2 lesions showing a different miRNA signature vs atrophy and destructive measures; and T2 lesions demonstrated the weakest link to both miRNA and disability. MicroRNAs have been proposed as biomarkers relevant to diagnosis, stage of disease, and response to treatment in MS. [33] [34] [35] 53 Magnetic resonance imaging techniques have long contributed to the diagnosis and monitoring of the disease. 3 Imaging advances have allowed measurement of heterogeneous pathologic processes, allowing clustering of patients based on these differences. 15, 56 To further understand the correlation between pathogenic and protective miRNAs and the relevance of their association with MRI in the present study, we performed an Ingenuity Pathway Analysis (https://targetexplorer.ingenuity.com/) to identify the most relevant experimentally observed gene targets of the miRNAs. Among the identified miRNAs, reduced expression of hsa.miR.143.3p correlated with increased T1:T2 ratio as a protective association. Previous studies indicate that hsa.miR.143.3p is inversely associated with brain tissue damage, with decreased levels in the serum in persons with Alzheimer disease, minimal cognitive impairment, and expression of hsa.miR.143 in neuronal stem cells is increased following the administration of insulinlike growth factor-1 58 (known to support the proliferation and enhanced survival of neuronal stem cells). 59 An analysis of the downstream cascade of hsa.miR.143 has exposed many potential targets, such as platelet-derived growth factor receptor-α, which play a significant role in the differentiation of oligodendrocytes, astrocytes, and neuroprogenitors. 60 Another target, mitogen-activated protein kinase, regulates differentiation of neuronal stem cells. 61 Taken together, the above results suggest the potential role of hsa.miR.143.3p in neuroprotection and repair, consistent with the present findings. Similarly, hsa.miR.142.5p, which also showed a protective correlation with T1:T2 ratio in our study, is known to be downregulated in cerebrospinal fluid and plasma from patients with Alzheimer disease. 62 As predicted by pathway analysis, hsa.miR.142.5p targets nuclear factor erythroidlike 2 and plays a key role in regulating genes involved in responses to free radical production upon injury and inflammation.
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The pathogenic miRNA, hsa.miR.92a.3p, showed a pathogenic relationship with T1:T2 ratio in our study. This miRNA belongs to the miR17-92 cluster, which is overexpressed in B cells 55 and plasma 34 in patients with MS vs healthy individuals serving as controls. In mice, miR17-92 favors proinflammatory Th17 polarization. 64 Furthermore, CD4 T-cell- a Estimated Spearman correlation coefficients are shown: the sign of the Spearman correlation indicates the direction of association between the miRNA expression level and the MRI measure of disease activity; its value reflects the strength of the association. In the interpretation of the meaning of the correlation coefficients, MRI-indicated severity was reflected in 2 possible directions: (1) for lesion severity (T2LV, T1:T2 ratio), a higher number represented increased disease severity, and (2) for atrophy measures (BPF, GMF), a higher number represented lower disease severity (less atrophy). The miRNA-MRI associations were observed in either direction:
(1) a pathogenic relationship shown by a higher miRNA expression was associated with greater severity of MRI-indicated involvement, and (2) a protective relationship shown by a higher miRNA expression was associated with lower severity of MRI-indicated involvement.
b Corrected for multiple comparisons using false discovery rate. 80 which is implicated in cell migration and infiltration. Loss of MMP14 in mice was shown to impair monocyte migration, transendothelial invasion, cytokine release, and infiltration of T cells into sites of inflammation. 81 These findings suggest that the presence of MMP14 due to low levels of this protective miRNA may correlate with disease progression by allowing entry of immune cells into the central nervous system. An important observation in this study was the topographic specificity of the relationships that we detected between miRNAs and MRI. Different sets of miRNAs were associated with spinal cord MRI measures of disease severity (lesions or atrophy) vs brain measures. This divergence is in BPV, whole-brain parenchymal volume; and T1:T2, ratio of T1 hypointense to T2 hyperintense lesion volume. Regarding lesion measures, T2LV showed the weakest association with either disability or miRNA expression. This observation is consistent with the notion that T2 lesions are nonspecific for the nature and severity of tissue injury, but the development of lesional T1 hypointensity 9 has a higher clinical relevance. This would explain why a T1:T2 lesion index shows more utility than T2LV in tracking therapeutic effects and providing clinical relevance in MS.
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Strengths and Limitations
To our knowledge, this is the first study that includes 2 large, independent patient cohorts; a highly specific, locked nucleic (Table 3 ). However, these correlations do not necessarily represent causation, although the evidence described above suggests such a relationship. Circulating miRNAs could be a byproduct of routine microvesicle secretion and cell death or be actively secreted to contribute to intracellular communication.
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Conclusions
Further studies in larger MS cohorts, other neurodegenerative diseases, and healthy individuals serving as controls may indicate whether the miRNAs identified in this study are exclusive to MS or generalized. A study with longitudinal design, with serum samples drawn at disease onset, would allow the evaluation of the ability of miRNA expression to determine subsequent disease evolution. Tables 1 and 2. 
